肝喜乐片联合复方二氯醋酸二异丙胺治疗乙型肝炎的临床研究

目的 探讨肝喜乐片联合复方二氯醋酸二异丙胺片治疗乙型肝炎的临床疗效。方法 选取2016年4月-2017年4月在西安市第九医院进行治疗的乙型肝炎患者82例作为研究对象，根据用药的差别将患者分为对照组（41例）和治疗组（41例）。对照组口服复方二氯醋酸二异丙胺片，40 mg/次，3次/d；治疗组在对照组基础上口服肝喜乐片，40 mg/次，3次/d。两组患者均治疗12周。观察两组患者的临床疗效，比较两组治疗前后的CLDQ量表评分、SF-36量表评分、肝功能指标、血清学指标、HBV-DNA和HBeAg转阴率。结果 治疗后，对照组和治疗组的总有效率分别为82.93%、97.56%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组CLDQ量表评分、SF-36量表评分均显著增高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组CLDQ量表评分、SF-36量表评分显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、总胆红素（TBIL）和总胆汁酸（TBA）水平均明显下降，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组肝功能指标显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清降钙素原（PCT）、白细胞介素-18（IL-18）、白细胞介素-22（IL-22）、基质金属蛋白酶-13（MMP-13）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组血清学指标显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组HBV-DNA和HBeAg转阴率显著高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 肝喜乐片联合复方二氯醋酸二异丙胺片治疗乙型肝炎可有效改善患者肝功能，降低机体炎症反应，促进HBV-DNA和HBeAg转阴，提高患者生活质量，具有一定的临床推广应用价值。

Clinical study on Ganxile Tablets combined with compound diisopropylamine dichloroacetate in treatment of hepatitis B

Objective To investigate the clinical efficacy of Ganxile Tablets combined with Compound Diisopropylamine Dichloroacetate Tablets in treatment of hepatitis B. Methods Patients (82 cases) with hepatitis B in Ninth Hospital of Xi''an from April 2016 to April 2017 were divided into control (41 cases) and treatment (41 cases) groups according to the difference of medication. Patients in the control group were po administered with Compound Diisopropylamine Dichloroacetate Tablets, 40 mg/time, three times daily. Patients in the treatment group were po administered with Ganxile Tablets on the basis of the control group, 40 mg/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and CLDQ scores, SF-36 scores, liver function indexes, serological indexes, and the negative rate of HBV-DNA and HBeAg in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.93% and 97.56%, respectively, and there was difference between two groups (P < 0.05). After treatment, CLDQ and SF-36 scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, CLDQ and SF-36 scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of ALT, AST, TBIL, and TBA in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the levels of liver function indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of PCT, IL-18, IL-22, and MMP-13 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the levels of serological indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the negative rates of HBV-DNA and HbeAg in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Ganxile Tablets combined with Compound Diisopropylamine Dichloroacetate Tablets in treatment of hepatitis B can effectively improve the liver function of patients, reduce the inflammatory reaction, promote negative transformation of HBV-DNA and HBeAg, and improve the quality of life of patients, which has a certain clinical application value.